标题
Recognizing and managing on toxicities in cancer immunotherapy
作者
关键词
-
出版物
TUMOR BIOLOGY
Volume 39, Issue 3, Pages 101042831769454
出版商
SAGE Publications
发表日期
2017-03-29
DOI
10.1177/1010428317694542
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- TNF activity and T cells
- (2018) Amit K. Mehta et al. CYTOKINE
- Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy
- (2016) Ting Yue et al. BMC CANCER
- Tumor Necrosis Factor-α, a Regulator and Therapeutic Agent on Breast Cancer
- (2016) Dongwu Liu et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
- (2015) T. W. Chen et al. ANNALS OF ONCOLOGY
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- The FDA Guidance on Therapeutic Cancer Vaccines: The Need for Revision to Include Preventive Cancer Vaccines or for a New Guidance Dedicated to Them
- (2015) O. J. Finn et al. Cancer Prevention Research
- Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety
- (2015) Saїd Azoury et al. CURRENT CANCER DRUG TARGETS
- Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment
- (2015) Ana P. Kiess et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety of Infusing Ipilimumab Over 30 Minutes
- (2015) Parisa Momtaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
- (2015) Andrew B Sharabi et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Ipilimumab in the real world
- (2015) Saif S. Ahmad et al. MELANOMA RESEARCH
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
- (2015) Richard W. Childs et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
- (2015) J Gao et al. ONCOGENE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
- (2015) Douglas B. Johnson et al. Cancer Immunology Research
- A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial
- (2015) Amabel CL Tan et al. Journal for ImmunoTherapy of Cancer
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Guidance for peptide vaccines for the treatment of cancer
- (2014) Yoshiyuki Yamaguchi et al. CANCER SCIENCE
- Is the "3+3" Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design
- (2014) O. E. Rahma et al. CLINICAL CANCER RESEARCH
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overexpressed oncogenic tumor-self antigens
- (2014) Robert K Bright et al. Human Vaccines & Immunotherapeutics
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- (2013) G. P. Linette et al. BLOOD
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab and Its Toxicities: A Multidisciplinary Approach
- (2013) L. A. Fecher et al. ONCOLOGIST
- Immunotherapy of cancer in 2012
- (2012) John M. Kirkwood et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Art in Oncology: How Patients Add Life to Their Days
- (2011) Evan J. Lipson JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery
- (2010) Krishna S. Gunturu et al. JOURNAL OF CLINICAL ONCOLOGY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
- (2010) Maria R Parkhurst et al. MOLECULAR THERAPY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients
- (2008) C. U. Louis et al. BLOOD
- Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma
- (2008) Axel Hauschild et al. CANCER
- Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
- (2008) R. L. Johnston et al. DIGESTIVE DISEASES AND SCIENCES
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started